Lumida
/IJT
⌘K
IJT

IJT

IJT
$166.46USD↑+0.48%+0.79 today

MARKET CAP

0

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$166 – $168

52W RANGE

$133
$180

AI Summary

Stalk
StalkMedium

IJT remains in a bullish medium-term environment, supported by its overall uptrend and price above the 50-day and 200-day moving averages. Recent pullback into the short-term EMAs reflects consolidation after an advance, offering a potential entry zone near the sliding 9/20 EMA support. Overbought/oversold context is neutral, requiring a clear acceptance in the EMA region before committing. Medium-term structure remains constructive in Stage 2, favoring deferred bullish engagement at support. Key risk is a breakdown below the 9/20 EMA that could signal deeper correction toward the 50-day SMA.

  • ↑Protagonist Therapeutics returned to profitability and raised FY guidance.
  • ↑Fed pause prospects lower Treasury yields, easing small-cap borrowing costs.
  • ↓IJT is exposed to volatile small-cap swings amid geopolitical tensions.
Full analysis →

Buying

4

institutions

Selling

1

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
JC

Jpmorgan Chase & Co

Q2 2026

BUY433.13 K76.54 M+12.38 K+30.1%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL132.68 K23.70 M+-1.80 K+21.8%0.04%
AC

Aqr Capital Management LLC

Q2 2026

BUY11.54 K2.06 M+1.26 K+38.5%0.00%
BI

Blackrock, Inc.

Q2 2026

BUY11.18 K2.00 M+2.50 K+59.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY10.40 K1.86 M+7.50 K+342.5%0.00%